Current Report Filing (8-k)
08 Novembre 2019 - 12:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 6th, 2019
CANNABICS
PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
|
Nevada
|
333-192759
|
20-3373669
|
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer No.)
|
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices
and Zip Code)
877 424-2429
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐ Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
|
Common Stock, par value $0.0001 per share
|
|
CNBX
|
|
OTCQB
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 – DEPARTURE OF DIRECTORS
OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On November 6th, 2019, the Board
of Directors nominated fellow Director and Board Member Gabriel Yariv as Chief Operating Officer.
Mr.
Yariv, 42, brings over 20 years of successful executive experience in the medical industry. Mr. Yariv was part of the
founding group of BreathID, an Oridion Medical business unit (now Medtronic) and its
subsequent spinoff company, Exalenz Bioscience, which develops and
manufactures advanced non-invasive diagnostic medical devices for gastrointestinal and liver conditions. Mr. Yariv
also co-founded SimuTec, a medical simulation and training company in Brazil that develops and commercializes advanced
personalized Virtual Reality training programs for physicians.
Mr. Yariv is actively engaged in
non-profit and philanthropic activities including ongoing business mentoring of entrepreneurs, founder of the Yariv
Foundation for Leadership, and current member of the Friends of the Israel Museum society. Mr. Yariv holds a BA (Cum
Laude) in History, Philosophy & Political science from Boston University, and a Certificate Course
in Cyberlaw from Harvard University.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
The following Exhibits are filed as part of this
Current Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Cannabics Pharmaceuticals Inc.
|
|
|
|
|
|
By:
|
/s/ Eyal Barad
|
|
|
|
Eyal Barad
Director, CEO
|
Date:
November 7, 2019
CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
